A Dolutegravir Open Label Protocol for HIV Infected, Adult and Adolescent Patients With Integrase Resistance
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DEAP
- Sponsors ViiV Healthcare
- 29 Dec 2012 Planned patient number is 1000 according to European Clinical Trials Database record.
- 29 Dec 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-001646-16).
- 29 Feb 2012 New trial record